Atherosclerosis
Volume 204, Issue 2 , Pages 465-470 , June 2009

NF-κB −94Ins/Del ATTG polymorphism modifies the association between dietary polyunsaturated fatty acids and HDL-cholesterol in two distinct populations

  • Bénédicte Fontaine-Bisson

      Affiliations

    • Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada
    • ,
  • Thomas M.S. Wolever

      Affiliations

    • Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada
    • Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
    • ,
  • Philip W. Connelly

      Affiliations

    • Keenan Research Centre of the Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, Canada
    • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada
    • Department of Medicine, University of Toronto, Toronto, Canada
    • ,
  • Paul N. Corey

      Affiliations

    • Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
    • ,
  • Ahmed El-Sohemy

      Affiliations

    • Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, Toronto, Canada
    • Corresponding Author InformationCorresponding author at: Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, 150 College Street, Room 350, Toronto, ON M5S 3E2, Canada. Tel.: +1 416 946 5776; fax: +1 416 978 5882.

Received 6 May 2008 ,Revised 14 August 2008 ,Accepted 30 October 2008.

References 

  1. Link J, Rohatgi A, de Lemos JA. HDL cholesterol: physiology, pathophysiology, and management. Curr Probl Cardiol. 2007;32:268–314
  2. Grunfeld C, Feingold KR. HDL and innate immunity: a tale of two apolipoproteins. J Lipid Res. 2008;49:1605–1606
  3. Grimble R. Dietary lipids and the inflammatory response. Proc Nutr Soc. 1998;57:535–542
  4. Calder P. Polyunsaturated fatty acids and inflammation. Prostaglandins Leukot Essent Fatty Acids. 2006;75:197–202
  5. Wijendran V, Hayes KC. Dietary n−6 and n−3 fatty acid balance and cardiovascular health. Annu Rev Nutr. 2004;24:597–615
  6. Ordovas J, Corella D, Cupples LA, et al. Polyunsaturated fatty acids modulate the effects of the APOA1 G-A polymorphism on HDL-cholesterol concentrations in a sex-specific manner: the Framingham Study. Am J Clin Nutr. 2002;75:38–46
  7. Fontaine-Bisson B, Wolever TMS, Chiasson JL, et al. Genetic polymorphisms of tumor necrosis factor-α modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A–I concentrations. Am J Clin Nutr. 2007;86:768–774
  8. Fontaine-Bisson B, El-Sohemy A. Genetic polymorphisms of tumor necrosis factor-alpha modify the association between dietary polyunsaturated fatty acids and plasma high-density lipoprotein-cholesterol concentrations in a population of young adults. J Nutrigenet Nutrigenom. 2008;1:215–223
  9. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-kappaB: its role in health and disease. J Mol Med. 2004;82:434–448
  10. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr. 2004;23:71–78
  11. Wang J, Ma H, Wang J, Li Q, Li Y, Li J. Long-term n−3 polyunsaturated fatty acids administration ameliorates arteriosclerosis by modulating T-cell activity in a rat model of small intestine transplantation. Clin Chim Acta. 2007;381:124–130
  12. Camandola S, Leonarduzzi G, Musso T, et al. Nuclear factor kB is activated by arachidonic acid but not by eicosapentaenoic acid. Biochem Biophys Res Commun. 1996;229:643–647
  13. Maziere C, Conte MA, Degonville J, Ali D, Maziere JC. Cellular enrichment with polyunsaturated fatty acids induces an oxidative stress and activates the transcription factors AP1 and NFkappaB. Biochem Biophys Res Commun. 1999;265:116–122
  14. Karban A, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35–45
  15. Park J, Farrance IK, Fenty NM, et al. NFKB1 promoter variation implicates shear-induced NOS3 gene expression and endothelial function in prehypertensives and stage I hypertensives. Am J Physiol Heart Circ Physiol. 2007;293:H2320–H2327
  16. Pickup J. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care. 2004;27:813–823
  17. Fontaine-Bisson B, Wolever TMS, Chiasson JL, et al. TNF-α 238G>A genotype alters post-prandial plasma levels of free fatty acids in obese individuals with type 2 diabetes. Metabolism. 2007;56:649–655
  18. Canadian nutrient file. Ottawa; 1997.
  19. Sniderman A, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem. 2003;36:499–504
  20. Willet W. Nutritional epidemiology. second edn. New York: Oxford University Press; 1998;
  21. Das U. Biological significance of essential fatty acids. JAPI. 2006;54:309–319
  22. Lee J, Sohn KH, Rhee SH, Hwang D. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem. 2001;276:16683–16689
  23. Zhao G, Etherton TD, Martin KR, et al. Anti-inflammatory effects of polyunsaturated fatty acids in THP-1 cells. Biochem Biophys Res Commun. 2005;336:909–917
  24. Kurylowicz A, Hiromatsu Y, Jurecka-Lubieniecka B, et al. Association of NFKB1-94ins/del ATTG promoter polymorphism with susceptibility to and phenotype of Graves’ disease. Genes Immun. 2007;8:532–538
  25. Baer M, Dillner A, Schwartz RC, Sedon C, Nedospasov S, Johnson PF. Tumor necrosis factor alpha transcription in macrophages is attenuated by an autocrine factor that preferentially induces NF-kappaB p50. Mol Cell Biol. 1998;18:5678–5689
  26. Hotamisligil G. Inflammation and metabolic disorders. Nature. 2006;444:860–867
  27. Morishima A, Ohkubo N, Maeda N, Miki T, Mitsuda N. NFkappaB regulates plasma apolipoprotein A–I and high density lipoprotein cholesterol through inhibition of peroxisome proliferator-activated receptor alpha. J Biol Chem. 2003;278:38188–38193
  28. Vanden Berghe W, Vermeulen L, Delerive P, De Bosscher K, Staels B, Haegeman G. A paradigm for gene regulation: inflammation, NF-kappaB and PPAR. Adv Exp Med Biol. 2003;544:181–196
  29. Nissen S, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007;297:1362–1373
  30. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64:303–305
  31. Bocos C, Göttlicher M, Gearing K, et al. Fatty acid activation of peroxisome proliferator-activated receptor (PPAR). J Steroid Biochem Mol Biol. 1995;53:467–473
  32. Paradis A, Fontaine-Bisson B, Bosse Y, et al. The peroxisome proliferator-activated receptor alpha Leu162Val polymorphism influences the metabolic response to a dietary intervention altering fatty acid proportions in healthy men. Am J Clin Nutr. 2005;81:523–530

PII: S0021-9150(08)00769-7

doi: 10.1016/j.atherosclerosis.2008.10.037

Atherosclerosis
Volume 204, Issue 2 , Pages 465-470 , June 2009

Article Tools

* Image Usage & Resolution